麝香保心丸与复方丹参滴丸治疗冠心病心绞痛疗效与安全性评价

Efficacy and safety evaluation on the treatment of coronary artery disease with Shexiang-baoxin pill and complex Danshen drop pill

目的系统评价麝香保心丸与复方丹参滴丸治疗冠心病心绞痛的临床疗效及安全性。方法计算机辅以手工检索有关文献数据库，搜索麝香保心丸与复方丹参滴丸治疗冠心病心绞痛的随机对照试验，并对其进行质量评价。用RevMan5．1．6软件对数据进行Meta分析。结果共纳入7个研究，包括603例患者。结果显示：试验组（麝香保心丸）较对照组（复方丹参滴丸）可改善冠心病心绞痛症状Egg=1．33，95％CI（1．21、1．45），P〈0．01]、心电图（ECG）表现[RR=1．55，95％CI（1．34、1．79），p〈0．01]。两组不良反应发生率分别为6．85％、14．38％；但差异无统计学意义（P〉0．05）。结论麝香保心丸在改善冠心病心绞痛临床症状方面优于复方丹参滴丸。

Objective To evaluate the clinical effect and safety of coronary artery disease （CAD） treated with Shexiang-baoxin pill and Complex Danshen drop pill. Methods Articles of randomized controlled trials （RCTs） about the treatment of CAD with Shexiang-baoxin pill and Complex Danshen drop pill were retrieved and the quality of these studies were analyzed by RevMan 5.1.6 software with Meta analysis. Results Seven studies involving 603 patients were included. The results of meta-analysis showed that the experimental group was better in ameliorating angina symptoms of angina pectofis patients [RR= 1.33, 95%CI （1.21,1.45）, P〈 0.01 ] and ECG [RR= 1.55, 95%CI （1.34,1.79）, P〈0.01 ] than the control group. Adverse reaction rate of the experimental group and the control group was 6.85% and 14.38% respectively, the difference was not statistically significant （P〉 0.05 ）. Conclusion The existing researches demonstrated that Shexiang-baoxin pill was better in treating CAD angina pectoris than Complex Danshen drop pill.